Petros Pharma Files 8-K on Shareholder Nominations
Ticker: PTPI · Form: 8-K · Filed: Sep 19, 2024 · CIK: 1815903
| Field | Detail |
|---|---|
| Company | Petros Pharmaceuticals, Inc. (PTPI) |
| Form Type | 8-K |
| Filed Date | Sep 19, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-activism, regulatory-filing
TL;DR
Petros Pharma filed an 8-K for shareholder nominations - could be a shake-up.
AI Summary
Petros Pharmaceuticals, Inc. filed an 8-K on September 19, 2024, reporting shareholder nominations pursuant to Exchange Act Rule 14a-11 as of September 16, 2024. The filing details the company's incorporation in Delaware and its principal executive offices located in New York, NY.
Why It Matters
This filing indicates potential changes or activism within Petros Pharmaceuticals, Inc. related to shareholder nominations, which could impact the company's future direction and governance.
Risk Assessment
Risk Level: medium — Filings related to shareholder nominations can signal internal disputes or activist investor involvement, potentially leading to uncertainty and volatility.
Key Players & Entities
- Petros Pharmaceuticals, Inc. (company) — Registrant
- September 16, 2024 (date) — Date of earliest event reported
- September 19, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- New York, New York (location) — Principal executive offices
- Exchange Act Rule 14a-11 (regulation) — Subject of the filing
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report shareholder nominations pursuant to Exchange Act Rule 14a-11.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is September 16, 2024.
In which state was Petros Pharmaceuticals, Inc. incorporated?
Petros Pharmaceuticals, Inc. was incorporated in Delaware.
What is the address of Petros Pharmaceuticals, Inc.'s principal executive offices?
The principal executive offices are located at 1185 Avenue of the Americas, 3rd Floor, New York, New York 10036.
What specific SEC rule is referenced in relation to the shareholder nominations?
The shareholder nominations are made pursuant to Exchange Act Rule 14a-11.
Filing Stats: 833 words · 3 min read · ~3 pages · Grade level 15.5 · Accepted 2024-09-19 16:05:18
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share PTPI The Nasdaq Stock Marke
Filing Documents
- tm2424409d1_8k.htm (8-K) — 24KB
- 0001104659-24-101333.txt ( ) — 195KB
- ptpi-20240916.xsd (EX-101.SCH) — 3KB
- ptpi-20240916_lab.xml (EX-101.LAB) — 33KB
- ptpi-20240916_pre.xml (EX-101.PRE) — 22KB
- tm2424409d1_8k_htm.xml (XML) — 4KB
08 Shareholder Director Nominations
Item 5.08 Shareholder Director Nominations On September 16, 2024, the Board of Directors of Petros Pharmaceuticals, Inc. (the "Company") determined that the Company's 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting") will be held on Wednesday, November 20, 2024, and that the record date for the determination of stockholders of the Company entitled to receive notice of and to vote at the 2024 Annual Meeting shall be the close of business on October 14, 2024. The time and location of the 2024 Annual Meeting will be as set forth in the Company's definitive proxy statement for the 2024 Annual Meeting to be filed with the Securities and Exchange Commission. Due to the fact that the date of the 2024 Annual Meeting has been changed by more than 30 days from the anniversary date of the 2023 Annual Meeting of Stockholders, the Company is providing the due date for submission of any qualified stockholder proposal or qualified stockholder nominations. Stockholders of the Company who wish to have a proposal considered for inclusion in the Company's proxy materials for the 2024 Annual Meeting pursuant to Rule 14a-8 under the Securities Exchange Act of 1934 (the "Exchange Act"), must ensure that such proposal is received by the Company's President and Chief Commercial Officer, Fady Boctor, at 1185 Avenue of the Americas, 3rd Floor, New York, New York 10036, on or before the close of business on September 29, 2024, which the Company has determined to be a reasonable time before it expects to begin in print and send its proxy materials in accordance with Rule 14a-5(f) and Rule 14a-8(e) under the Exchange Act. Any such proposal must also meet the requirements set forth in the rules and regulations of the Securities and Exchange Commission in order to be eligible for inclusion in the proxy materials for the 2024 Annual Meeting. In addition, in accordance with the requirements contained in the Company's amended and restated By-laws ("By-laws"), stockholders of the C
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PETROS PHARMACEUTICALS, INC. Date: September 19, 2024 By: /s/ Fady Boctor Name: Fady Boctor Title: President and Chief Commercial Officer